Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice-Reference-Cited by-同舟云学术

Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice

Published:2022-02-25 Issue:10 Volume:43 Page:2651-2665
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Lv Xin-huang,Cong Xiao-xia,Nan Jin-liang,Lu Xing-mei,Zhu Qian-li,Shen Jian,Wang Bei-bei,Wang Zhi-ting,Zhou Ri-yong,Chen Wei-an,Su Lan,Chen Xiao,Li Zheng-zheng,Lin Yi-nuo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.nature.com/articles/s41401-022-00878-7.pdf

Reference49 articles.

1. Birkeland KI, Jorgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5:709–17.

2. Xu C, Wang W, Zhong J, Lei F, Xu N, Zhang Y, et al. Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. Biochem Pharmacol. 2018;152:45–59.

3. Sun X, Han F, Lu Q, Li X, Ren D, Zhang J, et al. Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice. Diabetes. 2020;69:1292–305.

4. Nugrahaningrum D, Marcelina O, Liu C, Wu S, Kasim V. Dapagliflozin promotes neovascularization by improving paracrine function of skeletal muscle cells in diabetic hindlimb ischemia mice through PHD2/HIF-1α axis. Front Pharmacol. 2020;11:1104.

5. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes Pharmacotherapy and its effects on the Skeletal Muscle Energy Metabolism;Mini-Reviews in Medicinal Chemistry;2024-09

2. Author Correction: Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice;Acta Pharmacologica Sinica;2024-06-27

3. The antidiabetic SGLT2 inhibitor canagliflozin reduces mitochondrial metabolism in a model of skeletal muscle insulin resistance;Diabetic Medicine;2023-12-23

4. Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved;Clinical Nutrition;2023-12

5. Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis;Frontiers in Endocrinology;2023-09-15